ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Myricitrin promotes osteogenesis and prevents ovariectomy bone mass loss via the PI3K/AKT signalling pathway

Li, Jianliang; Mai, Jiale; Zhang, Meng; Ma, Yanhuai; He, Qi; Gong, Dawei; Xiao, Jiacong; Li, Miao; Chen, Weijian; Li, Zhen; Chen, Shuai; Pan, Zhaofeng; Li, Shaocong; Wang, Haibin*广州中医药大学; 郑州大学; 1; 5
Journal of Cellular Biochemistry2023-8DOI: 10.1002/jcb.30439
24阅读
引用收藏
分享

摘要

This study aimed to explore the effect of myricitrin on osteoblast differentiation in mice immortalised bone marrow mesenchymal stem cells (imBMSCs). Additionally, ovariectomy (OVX) mice were employed to examine the effect of myricitrin on bone trabecular loss in vivo. The effect of myricitrin on the proliferation of imBMSCs was evaluated using a cell counting kit-8 assay. Alizarin red staining, alkaline phosphatase staining were performed to elucidate osteogenesis. Furthermore, qRT-PCR and western blot determined the expression of osteo-specific genes and proteins. To screen for candidate targets, mRNA transcriptome genes were sequenced using bioinformatics analyses. Western blot and molecular docking analysis were used to examine target signalling markers. Moreover, rescue experiments were used to confirm the effect of myricitrin on the osteogenic differentiation of imBMSCs. OVX mice were also used to estimate the delay capability of myricitrin on bone trabecular loss in vivo using western blot, micro-CT, tartaric acid phosphatase (Trap) staining, haematoxylin and eosin staining, Masson staining and immunochemistry. In vitro, myricitrin significantly enhanced osteo-specific genes and protein expression and calcium deposition. Moreover, mRNA transcriptome gene sequencing and molecular docking analysis revealed that this enhancement was accompanied by an upregulation of the PI3K/AKT signalling pathway. Furthermore, copanlisib, a PI3K inhibitor, partially reversed the osteogenesis promotion induced by myricitrin. In vivo, western blot, micro-CT, hematoxylin and eosin staining, Masson staining, Trap staining and immunochemistry revealed that bone trabecular loss rate was significantly alleviated in the myricitrin low- and high-dose groups, with an increased expression of osteopontin, osteoprotegerin, p-PI3K and p-AKT compared to the OVX group. Myricitrin enhances imBMSC osteoblast differentiation and attenuate bone mass loss partly through the upregulation of the PI3K/AKT signalling pathway. Thus, myricitrin has therapeutic potential as an antiosteoporosis drug.

学科与关键词

关键词
bone marrow mesenchymal stem cellsmyricitrinosteoporosisPI3KAKT signalling pathway
相关
加载中…
  • Gentiopicroside promotes the osteogenesis of bone mesenchymal stem cells by modulation of β-catenin-BMP2 signalling pathway
    Jiang, Huaji; Zhong, Jialiang; Li, Wenjun; Dong, Jianghui; Xian, Cory J.; Shen, Yung-Kang; Yao, Lufeng; Wu, Qiang*; Wang, Liping*Journal of Cellular and Molecular Medicine, 2021, 25(23): 10825-10836.被引 7
  • Mechanism and Experimental Verification of Luteolin for the Treatment of Osteoporosis Based on Network Pharmacology
    Liang, Guihong; Zhao, Jinlong; Dou, Yaoxing; Yang, Yuan; Zhao, Di; Zhou, Zhanpeng; Zhang, Rui; Yang, Weiyi*; Zeng, Lingfeng*Frontiers in Endocrinology, 2022, 13: 866641.被引 9
  • Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway
    Xu, Yongxiang; Chen, Shichun; Huang, Linxuan; Han, Weichao; Shao, Yingying; Chen, Minyi; Zhang, Yusheng; He, Ruirong*; Xie, Baocheng*Frontiers in Pharmacology, 2022, 13: 894832.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Cellular Biochemistry
发表日期
2023-08
卷期
第 124 卷, 第 8 期
页码
1155-1172
DOI
10.1002/jcb.30439
语言
ENGLISH
成果收录
SCIE
资助标注
Guangzhou University of Chinese Medicine [2021xk53]; National Natural Science Foundation of China [82074462]

作者

  • L

    Li, Jianliang (第一作者)

    guangzhou univ chinese med · 1 · 2

  • M

    Mai, Jiale

    guangzhou univ chinese med · foshan hosp tradit chinese med

查看全部 14 位作者收起作者
  • Z

    Zhang, Meng

    henan univ · zhengzhou univ

  • M

    Ma, Yanhuai

    guangzhou univ chinese med · 1

  • H

    He, Qi

    guangzhou univ chinese med · 1

  • G

    Gong, Dawei

    1 · guangzhou univ chinese med

  • X

    Xiao, Jiacong

    guangzhou univ chinese med · 1

  • L

    Li, Miao

    guangzhou univ chinese med · 1

  • C

    Chen, Weijian

    2 · 5 · guangzhou univ chinese med

  • L

    Li, Zhen

    guangzhou univ chinese med · 2

  • C

    Chen, Shuai

    guangzhou univ chinese med · 1

  • P

    Pan, Zhaofeng

    guangzhou univ chinese med · 1

  • L

    Li, Shaocong

    guangzhou univ chinese med · 1

  • W

    Wang, Haibin (通讯)

    guangzhou univ chinese med · 1

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417